1. 1. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34: 2746–2751.
2. 2. Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: A systematic review. Scand Cardiovasc J 2013; 47(Suppl): 2–10.
3. 3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893–2962.
4. 4. Kato K, Hayakawa H, Atarashi H, Sugimoto T, Inoue H, Hiejima K, et al. Clinical trial of an ultra short acting β1-blocker; landiolol hydrochloride (ONO-1101), on paroxysmal atrial fibrillation or flutter and paroxysmal supraventricular tachycardia: An open label, dose finding study (late phase II study). Rinsho Iyaku (J Clin Ther Med) 1997; 13: 4873(53)–4901(81) [in Japanese].
5. 5. Kato K, Hayakawa H, Atarashi H, Sugimoto T, Inoue H, Hiejima K, et al. Clinical effect of intravenous infusion of landiolol hydrochloride (ONO-1101) on paroxysmal atrial fibrillation and atrial flutter: A phase III, double-blind study in comparison with placebo. Rinsho Iyaku (J Clin Ther Med) 1997; 13: 4903(83)–4924(104) [in Japanese].